` ILMN (Illumina Inc) vs S&P 500 Comparison - Alpha Spread

ILMN
vs
S&P 500

Over the past 12 months, ILMN has underperformed S&P 500, delivering a return of -36% compared to the S&P 500's 8% growth.

Stocks Performance
ILMN vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ILMN vs S&P 500

Loading
ILMN
S&P 500
Difference

Performance By Year
ILMN vs S&P 500

Loading
ILMN
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Illumina Inc vs Peers

S&P 500
ILMN
0KHE
TMO
DHR
207940
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Illumina Inc
Glance View

Economic Moat
None
Market Cap
13.6B USD
Industry
Life Sciences Tools & Services

In the world of genomics, Illumina Inc. stands as a pioneer, reshaping the landscape of genetic sequencing with a precision that borders on artistry. This San Diego-based company, founded in 1998, has become an industry cornerstone by unlocking the potential of the human genome through its advanced sequencing technologies. Illumina's success is anchored in its innovative creation of next-generation sequencing platforms, which enable researchers to analyze DNA at a scale and speed previously thought impossible. By providing the tools that sequence, analyze, and interpret vast amounts of genetic data, Illumina plays a crucial role in driving discoveries in personalized medicine, agriculture, and countless other fields. At the heart of Illumina's business model lies its suite of sequencing instruments and consumables, which form the backbone of its revenue generation. Their sequencing machines, ranging from behemoth instruments capable of cracking the human genome to compact devices used for focused applications, operate much like a razor-and-blade model. Once customers invest in Illumina's platforms, they continue to purchase consumable products, including reagents and advanced software, crucial for each sequencing run. This model not only fosters continuous engagement with their user base but also sustains a steady revenue stream. By expanding its reach into genomic-based clinical applications, Illumina has also started tapping into diagnostic markets, promising to transform the future of healthcare while ensuring sustained growth for the company.

ILMN Intrinsic Value
150.11 USD
Undervaluation 43%
Intrinsic Value
Price
Back to Top